Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Nivolumab 5Interleukin-2 4pembrolizumab 3Melphalan 3Ipilimumab 3apatinib 2tremelimumab 1tislelizumab 1fludarabine 1entinostat 1encorafenib 1camrelizumab 1binimetinib 1Tramadol 1Technetium 1Surgical Procedures, Operative 1Physical Examination 1Mohs Surgery 1Microscopy, Confocal 1Methotrexate 1Metastasectomy 1Immunotherapy 1Ibuprofen 1Fecal Microbiota Transplantation 1FMT protocol 1Dermoscopy 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × FMT protocol × Dermatologic × Clear all
NCT03166397 2023-01-26

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Sheba Medical Center

Phase 2 Recruiting
30 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡